DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 083051
Email this page to a colleague
» See Plans and Pricing
NDA 083051 describes MANNITOL 25%, which is a drug marketed by Abraxis Pharm, Fresenius Kabi Usa, Hospira, Igi Labs Inc, Intl Medication, Luitpold, Merck, and Watson Labs, and is included in nine NDAs. It is available from four suppliers. Additional details are available on the MANNITOL 25% profile page.
The generic ingredient in MANNITOL 25% is mannitol. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the mannitol profile page.
The generic ingredient in MANNITOL 25% is mannitol. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the mannitol profile page.
Summary for 083051
| Tradename: | MANNITOL 25% |
| Applicant: | Intl Medication |
| Ingredient: | mannitol |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 083051
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 12.5GM/50ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
